NEW YORK, March 29, 2018 -- The global sleeping aids market is expected to witness a CAGR of 6.8%, and is projected to reach USD 10.9 billion by 2024. The growth in the sleeping aids market is attributed to the rising incidences of sleep disorders across the globe. Moreover, growing awareness regarding the therapies for sleep disorders is also driving the growth in the sleeping aids market. The report segments Sleeping Aids market by Product (Medications, Sleep Apnea Devices, Sleep Laboratory Services, Others), Sleep Disorder (Insomnia, Sleep Apnea, Narcolepsy, Restless leg syndrome, Sleep Walking, Others), and Region (North America, Europe, Asia-Pacific, Rest of the World (RoW)). The report studies the global sleeping aids market over the forecast period (2018-2024).
The sleep aids are medications and devices which are used by people having trouble falling asleep. They include medications, sleep apnea devices, sleep laboratories, among others. A number of sleep disorders such as insomnia, restless legs,sleep apnea, narcolepsy among others can disrupt sleep quality. Disrupted sleep increases risk of obesity, diabetes, and cardiovascular diseases.
Browse full research report with TOC on “Global Sleeping Aids Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024” at: https://www.energiasmarketresearch.com/global-sleeping-aids-market-outlook/
Key findings from the report:
- The global sleeping aids market is expected to reach USD 10.9 billion by 2024
- Based on the Product , sleep apnea devices is projected to be the fastest growing segment during the forecast period
- On the basis of Sleep Disorder, the insomnia segment held the largest share of the global sleeping aids market in 2017 and is expected to retain its dominance during the forecast period
- North America held the major share of the sleeping aids market in 2017 and is projected to retain its dominance during 2018-2024
- The key players dealing in sleeping aids market are Merck & Co. Inc., Sanofi, Pfizer Inc., GlaxoSmithKline Plc, SleepMed Inc., Jazz Pharmaceuticals plc, Cadwell Industries, Inc., Natus Medical Incorporated, Drive Medical Ltd., Compumedics, among others
High Prevalence of Insomnia to Drive Global Sleeping Aids Market
Insomnia is the most common sleep disorder in the general population. Insomnia is a sleep disorder, in which people have difficulty in falling asleep or staying asleep throughout the night. Apart from cognitive therapy, sleeping pills and aids are also used frequently to treat insomnia. The incidence of insomnia is on the rise across the globe. An estimated 33% to % 50% of general population is affected by insomnia. Moreover, people over the age of 60 years are at a greater risk of insomnia. With a growing geriatric population across the globe, insomnia is projected to drive the global sleeping aids market in the forecast period.
Sleeping Aid Market - Regional insight
North America held the major share of the sleeping aids market in 2017 and is projected to retain its dominance during 2018-2024. The growth in the region is mainly driven by rising incidences of sleep disorders. The Asia-Pacific region is projected to grow at the highest CAGR during the forecast period due to growing old age population in the region.
Related Market Research Reports
- Global Cine Lens Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024
- Global Kombucha Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024
- Global Aloe Vera Extract Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024
About Energias Market Research Pvt. Ltd. -
Energias Market Research Pvt. Ltd. publishes high quality reports, in-depth market research studies, to help clients obtain investment level clarity on current business scenario, trends and segmentation for their future developments. We are committed to our client’s needs, by providing high quality custom reports solutions best fit for strategy development and implementation to high return of invest (RoI). We believe that exceptional problems need expertise to solve, and with the help of our industries expertise we are able to offer an in depth understanding of what’s crucial, what’s applicable, and what it takes to ensure accomplishment in any business or venture.
With a wide range of expertise from various industrial sectors and more than 50 industries that includes energy, chemical and materials, information communication technology, semiconductor industries, healthcare and daily consumer goods, etc. We strive to provide our clients with a one-stop solution for all research and consulting needs.
Contact Us
Alan Andrews
Business Development Manager
Phone: +1-716-239-4915
For any queries email us: [email protected]
To purchase report: [email protected]
Visit: https://www.energiasmarketresearch.com/


Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Apple Restores Telegram to App Store After Content Policy Violation
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 



